Tikun Olam Cannbit Pharmaceuticals Ltd
Tikun Olam-Cannbit Pharmaceuticals Ltd engages in the cultivation, production, marketing, storage, distribution, export and import, and sale of cannabis-based products in Israel. The company provides medical cannabis products for the treatment and relief of symptoms in a wide variety of medical indications. It also offers training and patient care services. Tikun Olam-Cannbit Pharmaceuticals Ltd … Read more
Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) - Net Assets
Latest net assets as of June 2025: ILA-19.66 Million ILA
Based on the latest financial reports, Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) has net assets worth ILA-19.66 Million ILA as of June 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA7.83 Million) and total liabilities (ILA27.50 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA-19.66 Million |
| % of Total Assets | -250.94% |
| Annual Growth Rate | N/A |
| 5-Year Change | -103.93% |
| 10-Year Change | N/A |
| Growth Volatility | 34437.06 |
Tikun Olam Cannbit Pharmaceuticals Ltd - Net Assets Trend (2017–2024)
This chart illustrates how Tikun Olam Cannbit Pharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Tikun Olam Cannbit Pharmaceuticals Ltd (2017–2024)
The table below shows the annual net assets of Tikun Olam Cannbit Pharmaceuticals Ltd from 2017 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA-5.35 Million | -116.18% |
| 2023-12-31 | ILA33.04 Million | -71.74% |
| 2022-12-31 | ILA116.92 Million | -18.70% |
| 2021-12-31 | ILA143.82 Million | +5.71% |
| 2020-12-31 | ILA136.06 Million | +36.24% |
| 2019-12-31 | ILA99.87 Million | +92371.30% |
| 2018-12-31 | ILA108.00K | +121.95% |
| 2017-12-31 | ILA-492.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Tikun Olam Cannbit Pharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 27487500000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA277.45 Million | 11174.18% |
| Total Equity | ILA2.48 Million | 100.00% |
Tikun Olam Cannbit Pharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of Tikun Olam Cannbit Pharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
TOTALLY PLC LS -10
F:UKXA
|
$75.72K |
|
PennantPark Floating Rate Capital Ltd
NYSE:PFLT
|
$75.79K |
|
Carlyle Tactical Private Credit Fund N
NMFQS:TAKNX
|
$75.83K |
|
Wealthfront Corporation Common Stock
NASDAQ:WLTH
|
$75.91K |
|
CRITICAL METALS DL-,0001
F:9O2
|
$75.61K |
|
Southern Financial Corporation
PINK:SFCO
|
$75.57K |
|
PRS Reit PLC
LSE:PRSR
|
$75.52K |
|
Rossell Techsys Limited
NSE:ROSSTECH
|
$75.47K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tikun Olam Cannbit Pharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 40,872,000 to 2,483,000, a change of -38,389,000 (-93.9%).
- Net loss of 40,101,000 reduced equity.
- New share issuances of 1,457,000 increased equity.
- Other factors increased equity by 255,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-40.10 Million | -1615.02% |
| Share Issuances | ILA1.46 Million | +58.68% |
| Other Changes | ILA255.00K | +10.27% |
| Total Change | ILA- | -93.92% |
Book Value vs Market Value Analysis
This analysis compares Tikun Olam Cannbit Pharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 67205.12x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | ILA-0.46 | ILA1964.00 | x |
| 2018-12-31 | ILA0.01 | ILA1964.00 | x |
| 2019-12-31 | ILA3.56 | ILA1964.00 | x |
| 2020-12-31 | ILA3.58 | ILA1964.00 | x |
| 2021-12-31 | ILA3.26 | ILA1964.00 | x |
| 2022-12-31 | ILA2.11 | ILA1964.00 | x |
| 2023-12-31 | ILA0.51 | ILA1964.00 | x |
| 2024-12-31 | ILA0.03 | ILA1964.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tikun Olam Cannbit Pharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1615.02%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -114.73%
- • Asset Turnover: 1.46x
- • Equity Multiplier: 9.67x
- Recent ROE (-1615.02%) is above the historical average (-2691.81%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | 0.00% | 0.00% | 0.00x | 0.00x | ILA-391.80K |
| 2018 | -19604.63% | 0.00% | 0.00x | 65.89x | ILA-21.18 Million |
| 2019 | -10.90% | 0.00% | 0.00x | 1.56x | ILA-20.88 Million |
| 2020 | -23.89% | -152.09% | 0.11x | 1.41x | ILA-46.73 Million |
| 2021 | -22.28% | -88.17% | 0.20x | 1.29x | ILA-47.31 Million |
| 2022 | -40.32% | -97.85% | 0.31x | 1.31x | ILA-60.20 Million |
| 2023 | -217.47% | -200.97% | 0.58x | 1.87x | ILA-92.97 Million |
| 2024 | -1615.02% | -114.73% | 1.46x | 9.67x | ILA-40.35 Million |
Industry Comparison
This section compares Tikun Olam Cannbit Pharmaceuticals Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $71,411,400
- Average return on equity (ROE) among peers: 5.92%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tikun Olam Cannbit Pharmaceuticals Ltd (TKUN) | ILA-19.66 Million | 0.00% | N/A | $75.63K |
| Canzon Israel Ltd (CNZN) | $11.02 Million | -7.32% | 0.37x | $18.43K |
| Intercure (INCR) | $256.20 Million | -2.30% | 0.10x | $367.38K |
| Rekah Pharmaceutical Industry Ltd (REKA) | $64.15 Million | 8.02% | 3.34x | $385.28K |
| Seach Medical Group Ltd (SEMG) | $25.69 Million | 31.20% | 0.30x | $278.78K |
| Together Startup Network Ltd (TGTR) | $-12.00K | 0.00% | 0.00x | $124.45K |